Cargando…
Repurposing of gastric cancer drugs against COVID-19
Corona Virus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has become a global pandemic. Additionally, the SARS-CoV-2 infection in the patients of Gastric Cancer (GC; the third leading cause of death in the world) pose a great challenge for the health...
Autores principales: | Sonkar, Charu, Doharey, Pawan Kumar, Rathore, Anuranjan Singh, Singh, Vishal, Kashyap, Dharmendra, Sahoo, Amaresh Kumar, Mittal, Nitish, Sharma, Bechan, Jha, Hem Chandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420180/ https://www.ncbi.nlm.nih.gov/pubmed/34537409 http://dx.doi.org/10.1016/j.compbiomed.2021.104826 |
Ejemplares similares
-
Impact of Gastrointestinal Symptoms in COVID-19: a Molecular Approach
por: Sonkar, Charu, et al.
Publicado: (2020) -
Helicobacter pylori and Epstein-Barr Virus Coinfection Stimulates Aggressiveness in Gastric Cancer through the Regulation of Gankyrin
por: Kashyap, Dharmendra, et al.
Publicado: (2021) -
Status of kinases in Epstein-Barr virus and Helicobacter pylori Coinfection in gastric Cancer cells
por: Sonkar, Charu, et al.
Publicado: (2020) -
Oral rinses in growth inhibition and treatment of Helicobacter pylori infection
por: Kashyap, Dharmendra, et al.
Publicado: (2020) -
Biochemical Characterization of Different Chemical Components of Parthenium hysterophorus and Their Therapeutic Potential against HIV-1 RT and Microbial Growth
por: Jaiswal, Jyotsna, et al.
Publicado: (2022)